###begin article-title 0
Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator-Activated Receptor gamma in Cardiac Fibrosis
###end article-title 0
###begin p 1
###xml 38 54 38 54 <email xmlns:xlink="http://www.w3.org/1999/xlink">wahsueh@tmhs.org</email>
Corresponding author: Willa A. Hsueh, wahsueh@tmhs.org
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-Cardiac fibrosis is an important component of diabetic cardiomyopathy. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands repress proinflammatory gene expression, including that of osteopontin, a known contributor to the development of myocardial fibrosis. We thus investigated the hypothesis that PPARgamma ligands could attenuate cardiac fibrosis.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 86 89 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 90 94 <span type="species:ncbi:10090">mice</span>
RESEARCH DESIGN AND METHODS-Wild-type cardiomyocyte- and macrophage-specific PPARgamma-/- mice were infused with angiotensin II (AngII) to promote cardiac fibrosis and treated with the PPARgamma ligand pioglitazone to determine the roles of cardiomyocyte and macrophage PPARgamma in cardiac fibrosis.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 40 43 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 60 63 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 355 358 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 861 864 833 836 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 359 363 <span type="species:ncbi:10090">mice</span>
###xml 865 869 <span type="species:ncbi:10090">mice</span>
RESULTS-Cardiomyocyte-specific PPARgamma-/- mice (cPPARgamma-/-) developed spontaneous cardiac hypertrophy with increased ventricular osteopontin expression and macrophage content, which were exacerbated by AngII infusion. Pioglitazone attenuated AngII-induced fibrosis, macrophage accumulation, and osteopontin expression in both wild-type and cPPARgamma-/- mice but induced hypertrophy in a PPARgamma-dependent manner. We pursued two mechanisms to explain the antifibrotic cardiomyocyte-PPARgamma-independent effects of pioglitazone: increased adiponectin expression and attenuation of proinflammatory macrophage activity. Adenovirus-expressed adiponectin had no effect on cardiac fibrosis and the PPARgamma ligand pioglitazone did not attenuate AngII-induced cardiac fibrosis, osteopontin expression, or macrophage accumulation in monocyte-specific PPARgamma-/- mice.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 149 150 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 236 237 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 305 306 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 389 390 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
CONCLUSIONS-We arrived at the following conclusions: 1) both cardiomyocyte-specific PPARgamma deficiency and activation promote cardiac hypertrophy, 2) both cardiomyocyte and monocyte PPARgamma regulate cardiac macrophage infiltration, 3) inflammation is a key mediator of AngII-induced cardiac fibrosis, 4) macrophage PPARgamma activation prevents myocardial macrophage accumulation, and 5) PPARgamma ligands attenuate AngII-induced cardiac fibrosis by inhibiting myocardial macrophage infiltration. These observations have important implications for potential interventions to prevent cardiac fibrosis.
###end p 6
###begin p 7
Published ahead of print at  on 28 May 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r4">4</xref>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r9">9</xref>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1050 1052 1050 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 1053 1055 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 1140 1142 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 1228 1230 1228 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 837 842 <span type="species:ncbi:10090">mouse</span>
###xml 1086 1090 <span type="species:ncbi:10090">mice</span>
###xml 1134 1138 <span type="species:ncbi:10090">mice</span>
Progressive cardiac fibrosis found in diabetic cardiomyopathy and postmyocardial infarction remodeling and during pressure overload can result in diastolic dysfunction leading to reduced myocardial contractility and, ultimately, heart failure (1-4). Both angiotensin II (AngII) and aldosterone promote cardiac hypertrophy, inflammation, and fibrosis, whereas their antagonism improves cardiac function and decreases mortality in heart failure (5-9). However, little is known about the cellular mechanism of these effects, and the prevalence of and mortality from heart failure continues to increase and is particularly common in subjects with diabetes (10). We have shown that osteopontin (OPN), a secreted inflammatory glycophosphoprotein, plays a pivotal role in cardiac fibrosis (11) and is often increased in the tissues of diabetic mouse models (11-13). Ventricular OPN expression is increased during heart failure, paralleling the increase in atrial natriuretic peptide (ANP) expression, and AngII prominently upregulates OPN in cardiac cells (12,13). Moreover, OPN knockout (KO) mice develop less cardiac fibrosis than control mice (11) and are partially protected against streptozotocin-induced diabetic cardiomyopathy (14).
###end p 9
###begin p 10
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 425 427 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 858 862 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that control expression of key genes that modulate pathways involved in fat, lipid, and glucose metabolism; inflammation; cell cycle; and immune responses (15). Synthetic PPARgamma ligands are insulin sensitizers and have profound anti-inflammatory effects, one of which is to decrease OPN expression in vascular and renal cells (16). Therefore, we hypothesized that PPARgamma agonists can attenuate myocardial fibrosis by reducing OPN expression in cardiomyocytes and/or macrophages, thereby decreasing cardiac inflammatory responses that can result in fibrosis. To test this hypothesis, we analyzed the effect of a PPARgamma agonist on cardiac hypertrophy and fibrosis in an AngII-stimulated model using both cardiomyocyte- and macrophage-specific PPARgamma KO mice and their wild-type (WT) littermate controls.
###end p 10
###begin title 11
RESEARCH DESIGN AND METHODS
###end title 11
###begin title 12
###xml 34 38 <span type="species:ncbi:10090">mice</span>
Generation of PPARgamma-deficient mice.
###end title 12
###begin p 13
###xml 47 50 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 97 106 85 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 148 150 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 273 275 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 283 284 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 337 346 321 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 376 385 356 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 502 505 474 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 744 753 712 721 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 768 770 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 771 773 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 161 176 <span type="species:ncbi:10090">transgenic mice</span>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 622 637 <span type="species:ncbi:10090">transgenic mice</span>
###xml 762 766 <span type="species:ncbi:10090">mice</span>
###xml 776 781 <span type="species:ncbi:10090">Mouse</span>
Cardiomyocyte-specific PPARgamma KO (cPPARgamma-/-) mice were bred by mating homozygous PPARgammaflox/flox DBA/2J mice (gift from Dr. F. Gonzalez) (17) with C3H transgenic mice expressing Cre recombinase under the control of the myosin light chain-2v (MLC2v-Cre) promoter (18). The F1 generation was backcrossed with homozygous PPARgammaflox/flox DBA mice to fix the PPARgammaflox/flox genotype, and successive generations were mated with their littermates. Macrophage-specific PPARgamma KO (mPPARgamma-/-) mice (kindly provided by Dr. P. Tontonoz, University of California Los Angeles) were generated by crossing C57Bl/6 transgenic mice expressing Cre recombinase under the control of the lysozyme promoter (LysM-Cre) into homozygous PPARgammaflox/flox C57Bl/6 mice (19,20). Mouse genotypes were determined by PCR (see the online appendix, available at ).
###end p 13
###begin title 14
Animal procedures.
###end title 14
###begin p 15
###xml 217 219 216 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 225 227 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 339 341 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 342 344 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 422 424 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 444 447 439 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 576 578 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 5 9 <span type="species:ncbi:10090">mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
Male mice (3 months of age) were fed chow diet (Harlan 8604) or chow diet supplemented with 2 mg pioglitazone/1g diet and, 2 days after starting diet, were infused with PBS or a pressor dose of AngII/PBS (2.5 mug . kg-1 . min-1; Calbiochem) for the indicated treatment intervals by subcutaneous implantation of osmotic minipumps (DURECT) (21-23). Systolic blood pressure (SBP) was measured weekly with a tail-cuff system (11). WT and cPPARgamma-/- mice were assessed by echocardiography before minipump implantation and after a 6-week AngII infusion, as previously described (24). Heart rates were determined during echocardiography (under anesthesia) and during SBP measurements. No differences were detected between any of the groups. All animal procedures used in this study were approved by the University of California Los Angeles Animal Research Committee.
###end p 15
###begin title 16
Morphometric analysis, cardiac fibrosis area, and macrophage content.
###end title 16
###begin p 17
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
Coronal heart sections were cut at the ventricle equator and fixed in 10% paraformaldehyde/PBS, paraffin embedded, and stained with Massons' trichrome to detect collagen expression. Microscope images were displayed on a high-resolution monitor, digitized by a video frame grabber (PCVISION Plus; Imaging Technology, St. Laurent, Canada) running on an IBM-compatible computer, and areas positively staining for collagen were quantified with a morphometric analysis program (Image Pro; Media Cybernetics, Silver Spring, MD). Contiguous high-power fields comprising an entire left ventricular section were analyzed for each sample. Cardiac fibrosis area (blue area) was expressed as a percentage relative to the entire cardiac cross-sectional area. Cardiomyocyte diameters were determined from 100 random fibers by a single operator blinded to the study protocol, essentially as previously described (25).
###end p 17
###begin title 18
Adiponectin overexpression.
###end title 18
###begin p 19
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 416 419 412 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 482 483 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
Adenovirus expressing mouse adiponectin (Ad-APN) was generated from the full-length cDNA (26), subcloned with an Adenovirus Expression Vector Kit (Takara Biomedical), propagated in HEK293 cells, and purified and quantified with BD Adeno-X Virus Purification and Rapid Titer kits (BD Biosciences). Adenovirus expressing green fluorescent protein (Ad-GFP) was similarly constructed as a control. Male WT and cPPARgamma-/- mice (3 months of age) were injected via tail vein with 1 x 108 plaque-forming units of virus 5 days before the start of a 6-week AngII infusion on chow diet. Plasma adiponectin levels were measured by ELISA (K1002-1; B-Bridge).
###end p 19
###begin title 20
Cardiac gene expression.
###end title 20
###begin p 21
RNA was isolated from ventricular heart sections with Trizol reagent (Gibco-BRL, Rockville, MD) and subsequently processed with RNeasy Mini Kits and RNase-Free DNase (QIAGEN) to remove genomic DNA from the resulting mRNA samples. Cardiac mRNA samples were reverse transcribed with random hexamers and MultiScribe RT polymerase (Applied Biosystems). Real-time quantitative RT-PCR was performed using an ABI PRISM 7700 to measure gene expression (see online appendix for specific primer/probe sets). Gene expression values were normalized against glyceraldehyde-3-phosphate dehydrogenase.
###end p 21
###begin title 22
###xml 6 11 <span type="species:ncbi:10090">mouse</span>
Adult mouse cardiomyocyte analyses.
###end title 22
###begin p 23
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 619 620 614 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 982 985 972 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 6 11 <span type="species:ncbi:10090">mouse</span>
###xml 575 581 <span type="species:ncbi:10090">murine</span>
###xml 845 850 <span type="species:ncbi:10090">mouse</span>
Adult mouse cardiomyocyte (AMCM) cultures were prepared according to Alliance for Cellular Signalling protocols (27). Immunohistochemistry was performed by standard procedures with specific antibodies for PPARgamma (SA-206; Biomol) and myosin (MF 20; Developmental Studies Hybridoma Bank). Macrophage migration assays were performed in 96-well chambers (CytoSelect CBA-105; Cell Biolabs) according to the manufacturer's instructions. Briefly, clarified conditioned media from a 48-h AMCM culture was placed in the lower compartment of the chamber, and a 100-mul aliquot of a murine J774A.1 macrophage suspension (5 x 105 cells/ml) in myocyte culture medium was added to the upper compartment. After 4.5 h, migratory cells were detected with CyQuant GR Dye (Molecular Probes). Western blot analyses of AMCM protein (20 mug) were performed with a mouse-OPN-specific antibody (MPIIIB; Developmental Studies Hybridoma Bank). Stimulation experiments were performed with WT and cPPARgamma-/- AMCMs, which were serum-deprived for 1 h, and then stimulated with AngII and aldosterone (1 mumol/l each) as indicated.
###end p 23
###begin title 24
Statistical analysis.
###end title 24
###begin p 25
###xml 55 62 53 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Figs. 2</xref>
###xml 64 65 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">4</xref>
###xml 71 72 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">5</xref>
###xml 343 344 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 594 595 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 684 692 680 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Tables 1</xref>
###xml 697 698 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">2</xref>
###xml 703 709 699 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3</xref>
###xml 1080 1081 1076 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1100 1101 1088 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1239 1240 1227 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">k</italic>
###xml 1242 1243 1230 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1755 1756 1743 1744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1831 1832 1819 1820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Data are presented as means +/- SEM. Data presented in Figs. 2, 4, and 5 were analyzed by one-way ANOVA due to their three-treatment design, using Tukey-Kramer multiple comparisons tests to determine treatment differences between individual means. Genotype differences between matched treatment groups were analyzed using two-tailed Student's t tests. In cases of unequal variance or non-normal distribution, nonparametric Mann-Whitney two-sample tests or Kruskal-Wallis one-way ANOVAs with Dunn post hoc analyses were performed to determine significant differences between individual means. A P value </=0.05 was considered statistically significant for all tests. Data presented in Tables 1 and 2 and Fig. 3 were analyzed by two-way ANOVAs due to their 2 x 2 factor design, and Bonferroni post hoc analyses were used to identify differences between specific groups. In cases of unequal variance or non-normal distribution, data were analyzed using a linear regression approach in which the continuous data variables were sorted in ascending order and then assigned rank values (k = 1, 2 em leader, n), with tied values averaged from the start to the end of the run. Ranked values were transformed into percentiles using the relationship k/(n + 1) and then transformed into quantiles of the standard normal distribution using the inverse cumulative normal function, resulting in a symmetric standard normal distribution with mean zero and variance one. Normal scores were regressed on indicator variables for treatment, genotype, and genotype-treament interaction. The genotype-treatment interaction variable was based on the product of genotype times treatment. For each outcome variable, the Bonferroni multiple test procedure was performed to provide t tests for all possible combinations of treatment and genotype. Bonferroni P values </=0.05 per number of tests were considered statistically significant for all analyses.
###end p 25
###begin title 26
RESULTS
###end title 26
###begin title 27
###xml 47 50 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Cardiomyocyte-specific PPARgamma KO (cPPARgamma-/-) mice have cardiac hypertrophy.
###end title 27
###begin p 28
###xml 10 13 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 188 190 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
###xml 220 229 212 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">flox/flox</sup>
###xml 372 375 360 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 467 468 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 461 468 445 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 547 550 523 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 660 661 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 654 661 626 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 842 845 798 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
###xml 230 235 <span type="species:ncbi:10090">mouse</span>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 853 857 <span type="species:ncbi:10090">mice</span>
cPPARgamma-/- mice were created by crossing MLC2v Cre mice, which selectively delete floxed target genes in ventricular cardiomyocytes starting at the early stages of cardiac development (28), into a homozygous PPARgammaflox/flox mouse background. Consistent with the fact that cardiac tissue contains several cell types in addition to including cardiomyocytes, cPPARgamma-/- mice ventricles expressed only 37% less PPARgamma mRNA than those of WT littermates (Fig. 1A). However, PPARgamma mRNA was not detectable in AMCMs isolated from cPPARgamma-/-, and confocal microscopy demonstrated complete ablation of cardiomyocyte PPARgamma protein expression (Fig. 1B). These data suggest that there is substantial PPARgamma expression by other myocardial cell types. Cardiac PPARalpha and PPARdelta mRNA expression were not different in cPPARgamma-/- and WT mice (data not shown), suggesting that there were no substantial changes in cardiac PPARalpha and PPARdelta mRNA expression to compensate for the loss of cardiomyocyte PPARgamma expression.
###end p 28
###begin p 29
###xml 10 13 6 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 232 239 228 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 397 400 385 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 408 415 396 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 868 875 852 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 402 406 <span type="species:ncbi:10090">mice</span>
cPPARgamma-/- mice demonstrated normal reproduction and life expectancy with no spontaneous pathological phenotype, despite mild cardiac hypertrophy associated with increased ventricular atrial natriuretic peptide (ANP) expression (Table 1). Conversely, the PPARgamma ligand pioglitazone increased ventricular heart-to-body weight ratios and ventricular ANP expression in WT, but not in cPPARgamma-/-, mice (Table 1). Thus, both cardiomyocyte PPARgamma deficiency and activation resulted in cardiac hypertrophy. Cardiomyocyte PPAR deficiency was also associated with differences in cardiomyocyte diameter and ventricular brain natriuretic peptide (BNP) expression, while pioglitazone treatment altered cardiomyocyte diameter and ventricular BNP mRNA expression and produced genotype-specific effects on heart-to-body weight ratios and ventricular ANP mRNA expression (Table 1, two-way ANOVA).
###end p 29
###begin p 30
###xml 66 67 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 191 194 184 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 217 218 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 219 220 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 211 220 204 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic>&#8211;<italic>D</italic></xref>
###xml 242 245 231 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 456 457 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 462 463 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 450 463 439 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic> and <italic>F</italic></xref>
###xml 492 495 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
Neither cardiac fibrosis nor transforming growth factor (TGF)-beta1 or fibronectin gene expression, assayed as surrogate markers of cardiac fibrosis, was significantly different in cPPARgamma-/- versus WT mice (Fig. 2A-D). However, cPPARgamma-/- mice demonstrated a 2.9-fold increase in cardiac expression of OPN, a proinflammatory monocyte chemoattractant, and a 1.4-fold increase in cardiac expression of CD68, a marker of macrophage accumulation (Fig. 2E and F), suggesting that cPPARgamma-/- mice may have significantly increased basal myocardial inflammation, which could promote enhanced myocardial injury during exposure to cardiac stress.
###end p 30
###begin title 31
###xml 25 28 21 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
AngII augments cPPARgamma-/- versus WT mice cardiac hypertrophy and fibrosis.
###end title 31
###begin p 32
###xml 241 243 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 244 246 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 378 381 370 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 505 512 497 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 667 674 659 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 731 732 720 721 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 927 930 912 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 954 955 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 960 961 945 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 948 961 933 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 983 984 965 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1065 1066 1047 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1071 1072 1053 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1059 1072 1041 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic> and <italic>D</italic></xref>
###xml 1109 1110 1088 1089 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1226 1229 1201 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1335 1338 1306 1309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1417 1418 1388 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1423 1424 1394 1395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1411 1424 1382 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic> and <italic>F</italic></xref>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 382 386 <span type="species:ncbi:10090">mice</span>
###xml 942 946 <span type="species:ncbi:10090">mice</span>
###xml 1230 1234 <span type="species:ncbi:10090">mice</span>
###xml 1338 1342 <span type="species:ncbi:10090">mice</span>
To evaluate the role of cPPARgamma in cardiac stress responses, mice were infused with AngII for 6 weeks at a dose known to cause hypertension, cardiac hypertrophy, and fibrosis without significant changes in plasma glucose or lipid levels (11,29). AngII infusion increased ventricular heart-to-body weight ratio and cardiomyocyte diameter in both genotypes, although cPPARgamma-/- mice demonstrated significantly greater increases than their WT littermates, despite similar SBP increases in both groups (Table 1). Ventricular ANP and BNP mRNA expression was also significantly increased by AngII in both genotypes but did not significantly differ between genotypes (Table 1). Cardiac fibrosis and myocardial expression of TGF-beta1 and fibronectin, two fibrosis-related genes, also significantly increased with AngII infusion in both genotypes. However, whereas AngII induced nearly twofold more cardiac fibrosis in cPPARgamma-/- than in WT mice (Fig. 2A and B), myocardial TGF-beta1 and fibronectin mRNA expression were similarly induced in both genotypes (Fig. 2C and D), suggesting that increased TGF-beta1 and fibronectin expression was not responsible for the increased cardiac fibrosis found in AngII-infused cPPARgamma-/- mice. AngII also increased myocardial OPN and CD68 expression in both genotypes but more so in cPPARgamma-/-mice, which had increased basal expression of these genes (PBS infusion, Fig. 2E and F). However, no changes in heart structure or function were detected by echocardiography in either genotype after AngII administration (data not shown).
###end p 32
###begin title 33
Pioglitazone attenuates AngII-induced cardiac fibrosis.
###end title 33
###begin p 34
###xml 560 567 548 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 754 755 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 760 761 748 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 748 761 736 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic> and <italic>B</italic></xref>
###xml 816 817 804 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 822 823 810 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 810 823 798 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>C</italic> and <italic>D</italic></xref>
###xml 852 853 840 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 858 859 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 846 859 834 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic> and <italic>F</italic></xref>
###xml 885 888 869 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 471 475 <span type="species:ncbi:10090">mice</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
###xml 889 893 <span type="species:ncbi:10090">mice</span>
To determine the ability of cPPARgamma activation to attenuate AngII-induced cardiac hypertrophy and fibrosis, mice were AngII-infused with or without simultaneous treatment with the PPARgamma ligand pioglitazone. Cardiomyocyte PPARgamma deficiency was associated with increases in heart-to-body weight ratios and cardiomyocyte diameters in AngII-infused mice. Pioglitazone treatment increased heart-to-body weight ratios and cardiac BNP mRNA expression in AngII-infused mice but did not alter SBP, cardiomyocyte diameters, or ventricular ANP mRNA expression (Table 1, two-way ANOVA). No genotype-specific effects of pioglitazone were detected in AngII-infused mice. Pioglitazone treatment also similarly attenuated AngII-induced cardiac fibrosis (Fig. 2A and B) and myocardial expression of fibrosis-related (Fig. 2C and D) and proinflammatory (Fig. 2E and F) genes in both cPPARgamma-/- mice and their WT littermate controls, suggesting that these antifibrotic and anti-inflammatory effects of pioglitazone are cardiomyocyte PPARgamma-independent.
###end p 34
###begin title 35
Adiponectin does not attenuate AngII-accelerated cardiac fibrosis.
###end title 35
###begin p 36
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 353 356 349 352 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 432 433 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 867 868 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 898 901 880 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 955 956 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1038 1039 1016 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1044 1045 1022 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1032 1045 1010 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic> and <italic>B</italic></xref>
###xml 1079 1080 1057 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1073 1080 1051 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>C</italic></xref>
###xml 1097 1098 1075 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1091 1098 1069 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>D</italic></xref>
###xml 1129 1132 1103 1106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1354 1357 1324 1327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">Mice</span>
###xml 814 818 <span type="species:ncbi:10090">mice</span>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
###xml 1139 1143 <span type="species:ncbi:10090">mice</span>
###xml 1358 1362 <span type="species:ncbi:10090">mice</span>
We hypothesized that the antifibrotic effect of pioglitazone on AngII-induced cardiac fibrosis could be mediated through increases in plasma adiponectin because adiponectin overexpression has been reported to attenuate cardiac hypertrophy in mice (30) and because pioglitazone treatment increased plasma adiponectin threefold in AngII-infused cPPARgamma-/- and WT mice (AngII 10.2 +/- 2.6 mug/ml vs. AngII+Pio 33.9 +/- 17.0 mug/ml; P = 0.0003). Mice were thus injected with Ad-APN or Ad-GFP 5 days before the start of a 6-week AngII infusion. Ad-APN markedly increased plasma adiponectin levels, reaching a peak of 50 times baseline (10-fold pioglitazone induction) at 2 weeks postinjection and declining to 10-fold baseline by study end. Ad-APN attenuated AngII-induced heart-to-body weight ratio increases in WT mice (5.85 +/- 0.18 Ad-GFP vs. 5.21 +/- 0.15 Ad-APN; P < 0.05) but not in cPPARgamma-/- mice (6.48 +/- 0.35 Ad-GFP vs. 6.35 +/- 0.18 Ad-APN; P = 0.79). However, Ad-APN did not attenuate AngII-induced cardiac fibrosis (Fig. 3A and B) or reduce myocardial OPN (Fig. 3C) or CD68 (Fig. 3D) mRNA expression in cPPARgamma-/- or WT mice. Thus, the increased systemic adiponectin levels after pioglitazone treatment were not responsible for attenuation of AngII-induced cardiac fibrosis and OPN and CD68 expression previously observed in cPPARgamma-/- mice with pioglitazone treatment.
###end p 36
###begin title 37
###xml 9 12 5 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
PPARgamma-/- cardiomyocytes support increased macrophage chemotaxis.
###end title 37
###begin p 38
###xml 18 21 14 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 117 118 113 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 123 124 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 111 124 107 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>E</italic> and <italic>F</italic></xref>
###xml 192 194 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 228 231 220 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 431 434 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 502 503 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 496 503 484 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic></xref>
###xml 712 715 696 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 895 896 879 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 889 896 873 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic></xref>
###xml 919 922 899 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1043 1046 1019 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1169 1170 1145 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1163 1170 1139 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 1260 1263 1236 1239 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 22 26 <span type="species:ncbi:10090">mice</span>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
Because cPPARgamma-/- mice demonstrated significantly more myocardial expression of OPN and CD68 than WT mice (Fig. 2E and F) and because macrophages have been implicated in cardiac fibrosis (31), we hypothesized that cPPARgamma-/- OPN expression could promote monocyte accumulation within the myocardium that could in turn promote cardiac injury in response to proinflammatory stimuli. We found that AMCMs isolated from cPPARgamma-/- mice expressed significantly more OPN protein than WT AMCMs (Fig. 4A). AMCM cultures were stimulated with AngII and aldosterone to simulate the cardiomyocyte environment during in vivo AngII infusion because AngII markedly induces adrenal aldosterone secretion. Both cPPARgamma-/- and WT AMCMs demonstrated increased OPN mRNA expression when cultured with AngII and aldosterone, but the addition of pioglitazone prevented OPN induction only in WT AMCMs (Fig. 4B). Moreover, cPPARgamma-/- AMCMs expressed over fivefold more OPN than WT AMCMs under all culture conditions, and conditioned media from cPPARgamma-/- AMCMs stimulated with AngII and aldosterone induced 1.5-fold greater macrophage migration than WT AMCM supernatant (Fig. 4C). These in vitro data support in vivo observations that increased OPN expression in cPPAR-/- cardiomyocytes contributes to increased cardiac macrophage accumulation.
###end p 38
###begin title 39
Attenuation of fibrosis by pioglitazone requires macrophage PPARgamma.
###end title 39
###begin p 40
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 108 121 108 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>B</italic> and <italic>C</italic></xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 314 317 306 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 364 366 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 524 527 508 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 607 610 587 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 723 726 699 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 741 744 713 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 994 1001 962 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 1012 1013 980 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1006 1013 974 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 1167 1174 1131 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t1">Table 1</xref>
###xml 1185 1186 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1179 1186 1143 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 1226 1229 1186 1189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1244 1247 1200 1203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1322 1329 1278 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 1399 1401 1355 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5A</italic>
###xml 1402 1403 1358 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1394 1403 1350 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. <italic>5A</italic>&#8211;<italic>D</italic></xref>
###xml 1558 1565 1510 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="t2">Table 2</xref>
###xml 1673 1676 1621 1624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1698 1701 1642 1645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1714 1715 1658 1659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1716 1717 1660 1661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1708 1717 1652 1661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic>&#8211;<italic>D</italic></xref>
###xml 1860 1863 1796 1799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1871 1872 1807 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1865 1872 1801 1808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 1895 1898 1827 1830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1913 1916 1841 1844 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1929 1930 1857 1858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1923 1930 1851 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 319 323 <span type="species:ncbi:10090">mice</span>
###xml 535 539 <span type="species:ncbi:10090">mice</span>
###xml 618 622 <span type="species:ncbi:10090">mice</span>
###xml 745 749 <span type="species:ncbi:10090">mice</span>
###xml 825 829 <span type="species:ncbi:10090">mice</span>
###xml 918 923 <span type="species:ncbi:10090">mouse</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
###xml 1121 1125 <span type="species:ncbi:10090">mice</span>
###xml 1248 1252 <span type="species:ncbi:10090">mice</span>
###xml 1552 1556 <span type="species:ncbi:10090">mice</span>
###xml 1702 1706 <span type="species:ncbi:10090">mice</span>
###xml 1917 1921 <span type="species:ncbi:10090">mice</span>
Because AngII markedly enhanced cardiomyocyte OPN expression, cardiomyocyte-mediated macrophage chemotaxis (Fig. 4B and C), and in vivo macrophage recruitment (32), we hypothesized that pioglitazone could attenuate fibrosis via anti-inflammatory actions on macrophages. Macrophage-specific PPARgamma KO (mPPARgamma-/-) mice, previously described by Babaev et al. (33), were thus analyzed using the same treatment protocol to address the role of macrophage PPARgamma in cardiac fibrosis. After 6 weeks, PBS-infused mPPARgamma-/- and WT mice demonstrated similar cardiac fibrosis, and AngII-infused mPPARgamma-/- and WT mice demonstrated similar cardiac fibrosis increases, which were substantially greater than in cPPARgamma-/- and cPPARgamma+/+ mice (data not shown), likely due to the different genetic backgrounds of these mice. To study the effect of pioglitazone on similar levels of cardiac fibrosis in these two mouse models, mPPARgamma mice were studied after 2 weeks of AngII infusion (Table 2 and Fig. 5A), at which time they developed cardiac hypertrophy and fibrosis levels comparable with those of cPPARgamma mice that received 6 weeks of AngII infusion (Table 1 and Fig. 3A). After 2 weeks, PBS-infused mPPARgamma-/- and mPPARgamma+/+ mice had similar heart-to-body weight ratios and cardiomyocyte diameters (Table 2), cardiac fibrosis and myocardial OPN and CD68 mRNA expression (Fig. 5A-D), and circulating monocyte levels (data not shown). Pioglitazone increased AngII-mediated cardiac hypertrophy independent of genotype in mPPARgamma mice (Table 2, two-way ANOVA), but reduced AngII-mediated cardiac fibrosis and OPN and CD68 gene expression in mPPARgamma+/+ but not in mPPARgamma-/- mice (Fig. 5A-D). This data suggests that macrophage mPPARgamma was required for the antifibrotic actions of pioglitazone observed in AngII-infused mPPARgamma+/+ (Fig. 5A) as well as cPPARgamma-/- and cPPARgamma+/+ mice (Fig. 3A). Thus, the macrophage appears to be a key mediator of fibrosis in the heart.
###end p 40
###begin title 41
DISCUSSION
###end title 41
###begin p 42
###xml 114 116 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 224 226 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 494 496 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 563 564 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 612 614 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 775 777 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 783 784 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 914 916 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 917 919 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 1073 1076 1053 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1274 1277 1250 1253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1330 1333 1302 1305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1414 1417 1382 1385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1460 1463 1424 1427 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1546 1549 1506 1509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 1577 1580 1533 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1963 1964 1916 1917 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2017 2020 1966 1969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2035 2038 1980 1983 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 2066 2069 2007 2010 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2084 2087 2021 2024 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 2132 2133 2069 2070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1</italic>
###xml 2269 2270 2206 2207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2</italic>
###xml 2357 2358 2290 2291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">3</italic>
###xml 2432 2433 2365 2366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4</italic>
###xml 2525 2526 2454 2455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
###xml 620 628 <span type="species:ncbi:9606">patients</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
###xml 1278 1282 <span type="species:ncbi:10090">mice</span>
###xml 2039 2043 <span type="species:ncbi:10090">mice</span>
###xml 2088 2092 <span type="species:ncbi:10090">mice</span>
Although PPARgamma ligands can promote edema by increasing renal sodium reabsorption to exacerbate heart failure (34), the metabolic and anti-inflammatory effects of these agents are implicated in cardiovascular protection (35). Indeed, a recent analysis of patients developing congestive heart failure with thiazolidinediones suggests that correction of heart failure is not associated with worsening of ejection fraction, which usually occurs with repeated bouts of congestive heart failure (36). We used an AngII-dependent cardiac fibrosis model in this study 1) because AngII is a potent profibrotic factor (37) and patients with type 2 diabetes may have increased renin-angiotensin-aldosterone system (RAAS) activity due to increases in adipose-derived angiotensinogen (38) and 2) because, importantly, PPARgamma ligand effects on fibrosis could be studied in the absence of plasma glucose and lipid changes (11,29). We report herein that PPARgamma ligands attenuate cardiac fibrosis via a mechanism that requires monocyte, but not cardiomyocyte, PPARgamma. cPPARgamma-/- mice had no apparent pathology, except for a mild cardiac hypertrophy, in the absence of an external stress. However, AngII infusion nearly doubled cardiac fibrosis and OPN expression in cPPARgamma-/- mice relative to WT littermates. Isolated cPPARgamma-/- AMCMs had more than a fivefold increase in OPN mRNA expression versus cPPARgamma+/+ AMCMs, and conditioned media of cPPARgamma-/- AMCMs demonstrated 1.5-fold more monocyte chemoattractant activity than cPPARgamma+/+ AMCMs. Increased cPPARgamma-/- cardiomyocyte OPN expression may contribute to increased monocyte accumulation both in the basal state and following AngII infusion, when inflammation plays a prominent role in cardiac fibrosis. However, noncardiomyocyte-driven inflammation appears critical to the cardiac fibrosis process in this model because pioglitazone attenuated cardiac fibrosis and ventricular OPN, TGF-beta1, fibronectin, and CD68 mRNA expression in cPPARgamma-/- and cPPARgamma+/+ mice, but not in mPPARgamma-/- and mPPARgamma+/+ mice. Taken together, our data suggest that 1) mechanisms contributing to initiation of cardiac hypertrophy are different from those contributing to initiation of cardiac fibrosis, 2) cardiomyocyte PPARgamma activation or deficiency contributes to cardiac hypertrophy, 3) inflammation is a significant driver of AngII-induced cardiac fibrosis, 4) both cardiomyocyte and macrophage PPARgamma regulate cardiac macrophage infiltration, and 5) PPARgamma ligands attenuate AngII-induced cardiac fibrosis by inhibiting macrophage infiltration into the myocardium.
###end p 42
###begin p 43
###xml 382 384 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 515 518 507 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 376 380 <span type="species:ncbi:10090">mice</span>
###xml 519 523 <span type="species:ncbi:10090">mice</span>
###xml 651 655 <span type="species:ncbi:10090">mice</span>
Since pioglitazone treatment prominently increased plasma adiponectin, we also examined whether increased plasma adiponectin might explain the antifibrotic effect of pioglitazone, independent of cardiomyocyte PPARgamma activity. Cardiac hypertrophy and mortality, induced by aortic constriction or AngII infusion, is rescued by adenoviral adiponectin in adiponectin-deficient mice (30). However, whereas pioglitazone improved AngII-induced cardiac fibrosis and increased plasma adiponectin in both WT and cPPARgamma-/- mice, adiponectin overexpression had no effect on cardiac fibrosis in either genotype and attenuated cardiac hypertrophy only in WT mice. Thus, adiponectin does not appear to impact fibrosis. The question of why cardiomyocyte PPARgamma was required for attenuation of cardiac hypertrophy by adiponectin requires further investigation.
###end p 43
###begin p 44
###xml 151 153 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 154 156 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 183 185 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 475 477 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 897 899 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
###xml 1207 1209 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 1210 1212 1182 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 1199 1205 <span type="species:ncbi:9606">humans</span>
Cardiac PPARgamma deficiency, in this study and previous reports, is associated with cardiac hypertrophy and greater hypertrophic responses to stress (39,40). Similar to Duan et al. (40), we found that PPARgamma activation induced cardiac hypertrophy, which was not detectable by echocardiography and which occurred without spontaneous systolic or diastolic dysfunction. Cardiac hypertrophy in their model was associated with activation of the nuclear factor kappaB pathway (40). In their study, however, the PPARgamma ligand rosiglitazone induced cardiac hypertrophy in both the WT and KO animals, leading the authors to conclude that cardiomyocyte PPARgamma only partially mediated the effect. They proposed that rosiglitazone stimulated the p38 mitogen-activated protein kinase pathway to activate cardiac hypertrophy through a mechanism distinct from that mediated by cardiomyocyte PPARgamma (40). Cardiac phenotype differences between the present study and that of Duan et al. may result from genetic differences in the two models (MLC2v Cre vs. alphaMHC Cre) or differences in pioglitazone versus rosiglitazone effects. Neither thiazolidinedione has been shown to cause cardiac hypertrophy in humans (41,42).
###end p 44
###begin p 45
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 998 1000 998 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 352 358 <span type="species:ncbi:9606">humans</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
RAAS-induced inflammation contributes to the pathogenesis of cardiac fibrosis. Cardiac OPN expression is increased by activation of both cardiac AngII type 1 receptors and mineralocorticoid receptors (37). We previously reported that cardiac OPN expression is elevated in rodent models of cardiac hypertrophy and in ventricles of explanted hearts from humans receiving cardiac transplants (13). OPN promotes cardiac fibroblast attachment to the extracellular matrix (ECM), and cardiac fibroblast growth and ECM production (12,43), whereas OPN-deficient mice have attenuated cardiac fibrosis, suggesting that OPN is a key profibrotic factor in the heart (11,44,45). None of these studies differentiated between the contributions of cardiomyocyte versus macrophage OPN deficiency in attenuating cardiac fibrosis, although we reported that macrophage OPN deficiency attenuated AngII-accelerated atherosclerosis by decreasing macrophage attachment and chemotaxis and by promoting macrophage apoptosis (46).
###end p 45
###begin p 46
###xml 129 132 125 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 253 256 245 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 413 416 401 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 504 507 488 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 823 827 <span type="species:ncbi:10090">mice</span>
In this study, we found that cardiac OPN expression and macrophage accumulation were markedly increased in nonstressed cPPARgamma-/- mice. Although increased cardiac OPN expression could result from increased macrophage accumulation, isolated cPPARgamma-/- AMCMs also expressed more OPN than WT AMCMs, suggesting that both macrophages and cardiomyocytes contribute to elevated cardiac OPN expression in cPPARgamma-/- mice. We did not, however, observe increased cardiac fibrosis in nonstressed cPPARgamma-/- mice, even in 1-year-old mice, indicating that the increased cardiac OPN expression was not associated with spontaneous cardiac pathology during this time frame. Because OPN is a macrophage chemoattractant, increased cardiac OPN secretion could lead to cardiac macrophage accumulation, as observed in AngII-infused mice, further increasing myocardial OPN expression and creating a vicious cycle that could escalate the cardiac fibrotic process.
###end p 46
###begin p 47
###xml 245 248 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 260 263 248 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 280 283 264 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 472 474 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 577 579 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 284 288 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
###xml 1068 1074 <span type="species:ncbi:9606">humans</span>
This study underscores a role for macrophages in cardiac fibrosis and a possible role for PPARgamma ligands in the inhibition of cardiac fibrosis. Pioglitazone decreased cardiac fibrosis, macrophage accumulation, and OPN expression in cPPARgamma-/-, cPPARgamma+/+, and mPPARgamma +/+ mice, suggesting that macrophage accumulation and OPN expression is a major mechanism of cardiac fibrosis induced by RAAS activation. PPARgamma ligands suppress macrophage OPN expression (47), attenuate macrophage expression of several pro-inflammatory genes, and inhibit monocyte chemotaxis (48). Pioglitazone did not, however, attenuate cardiac fibrosis in mice with a monocyte-specific PPARgamma deficiency, suggesting that PPARgamma is required for the attenuation of monocyte inflammatory behavior that leads to cardiac fibrosis. Thus, the anti-inflammatory actions of PPARgamma ligands may be useful for attenuating cardiac fibrosis and may be an adjunct therapy to RAAS inhibition. However, these putative anti-inflammatory cardiac actions of PPARgamma need to be confirmed in humans. Further studies are also necessary to determine whether the metabolic and insulin-sensitizing effects of PPARgamma ligands are also cardiomyocyte protective in diabetes and obesity and whether weaker insulin-sensitizing PPARgamma ligands that cause less edema, which are currently under development, also attenuate cardiac fibrosis.
###end p 47
###begin title 48
Supplementary Material
###end title 48
###begin title 49
Online-Only Appendix
###end title 49
###begin p 50
This work was supported by National Heart, Lung, and Blood Institute Grant HLO46916 and National Institute of Diabetes and Digestive and Kidney Diseases Grant HLO70526 to W.H. and by Takeda Pharmaceuticals North America. E.C. was supported by the German Heart Foundation. The study was partially supported by a research grant from Takeda Pharmaceuticals North America, which also provided the pioglitazone used for this study.
###end p 50
###begin p 51
We thank Sarah Duong, Van Chu, Rima Boyadjian, and Longsheng Hong for excellent technical assistance.
###end p 51
###begin title 52
REFERENCES
###end title 52
###begin p 53
###xml 54 55 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 146 149 138 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 212 215 200 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 236 237 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 252 253 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 274 275 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 322 323 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 380 383 364 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 150 154 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
PPARgamma expression in cardiac ventricles and AMCMs. A: Real-time quantitative RT-PCR of ventricular tissue of 4-month-old male WT and cPPARgamma-/- mice and pooled AMCMs from male WT (black bars) and cPPARgamma-/- (gray bars) hearts (n = 3/genotype; P < 0.05 by Student's t test). Values are normalized to the WT group. B: Immunohistochemistry of AMCMs of male WT and cPPARgamma-/- (KO) mice. Cardiomyocytes shown are representative of at least three independent experiments. (Please see  for a high-quality digital representation of this figure.)
###end p 53
###begin p 54
###xml 117 120 113 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 134 135 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 212 213 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 239 240 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 365 366 358 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 368 369 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 395 396 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 412 413 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 439 440 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 448 449 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 475 476 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 489 490 482 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 516 517 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 660 661 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 689 690 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 703 704 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 737 738 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
Pioglitazone treatment similarly attenuates fibrosis and pro-inflammatory gene expression in AngII-infused cPPARgamma-/- and WT mice. A: Cardiac fibrosis was quantified by measuring midventricular collagen area (n = 5-13/treatment group). B: Representative images of cardiac collagen expression (blue area) in AngII- and AngII+Pio-treated mice. Ventricular TGF-beta1 (n = 6-13/treatment group) (C), fibronectin (n = 5-14/treatment group) (D), OPN (n = 6-12/treatment group) (E), and CD68 (n = 5-15/treatment group) (F) mRNA expression was measured by real-time quantitative RT-PCR. Black and gray bars indicate cPPARgamma WT and KO animal data, respectively. *P < 0.05 vs. WT by Student's t test; daggerP < 0.05 vs. PBS and double daggerP < 0.05 vs. AngII by one-way ANOVA. Pio, pioglitazone. (Please see  for a high-quality digital representation of this figure.)
###end p 54
###begin p 55
###xml 167 168 163 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 343 344 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 409 410 405 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 451 452 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 464 465 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 496 499 488 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 513 514 505 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 703 706 691 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 812 813 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 900 903 884 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 507 511 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
###xml 854 858 <span type="species:ncbi:10090">mice</span>
Adiponectin does not mediate the antifibrotic effect of pioglitazone in the heart. Male cPPARgamma mice were infected with adenovirus overexpressing Ad-GFP or Ad-APN (n = 4-5/treatment group) 5 days before the start of a 6-week AngII infusion on chow diet. Cardiac fibrosis was quantified by measuring midventricular collagen expression area (A), and representative images of collagen expression (blue area) (B) are shown for each group. Cardiac OPN (C) and CD68 (D) mRNA expression in cPPARgamma-/- and WT mice (n = 3-5/treatment group) was measured by real-time quantitative RT-PCR. AngII-mediated increases in cardiac fibrosis, OPN, and CD68 expression were not significantly attenuated in cPPARgamma-/- or WT mice injected with Ad-GFP vs. Ad-APN, and adenovirus effects did not differ according to genotype (P > 0.05 by two-way ANOVA). Values for WT mice are depicted by black bars and cPPARgamma-/- values by gray bars. (Please see  for a high-quality digital representation of this figure.)
###end p 55
###begin p 56
###xml 9 12 5 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 59 60 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 205 208 194 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 216 217 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 245 246 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 254 255 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 287 288 276 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 499 502 482 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 525 526 508 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 556 557 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 599 600 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 699 702 673 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 934 935 907 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 962 963 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 602 607 <span type="species:ncbi:10090">Mouse</span>
###xml 834 839 <span type="species:ncbi:10090">mouse</span>
PPARgamma-/- cardiomyocytes have increased OPN expression. A: Representative Western blot and graph of beta-actin normalized OPN expression in cultured AMCMs (24 h) isolated from 10-month WT and cPPARgamma-/- mice (*P < 0.05 vs. WT by Student's t test). B: OPN mRNA expression in AMCMs (n = 3/treatment group) after 24 h culture with 0.1% DMSO (control) or AngII and aldosterone (AngII+Aldo, 1 mumol/l each) with or without 1 mumol/l pioglitazone. WT values are depicted by black bars and cPPARgamma-/- values by gray bars (*P < 0.05 vs. control and daggerP < 0.05 vs. AngII+Aldo by one-way ANOVA). C: Mouse J774A.1 macrophage migration in response to 48-h conditioned media isolated from cPPARgamma-/- (KO) and WT AMCM cultures. Nonconditioned myocyte culture media supplemented with (OPN) or without (control) 20 mug/ml recombinant mouse OPN served as positive and negative controls, respectively. Data are presented as % control (*P < 0.05 vs. control; daggerP < 0.05 vs. WT by one-way ANOVA). Pio, pioglitazone.
###end p 56
###begin p 57
###xml 107 110 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 130 133 122 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 141 142 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 205 206 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 232 233 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 318 319 310 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 331 332 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 398 399 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 471 474 459 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 502 503 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 531 532 519 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 545 546 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 580 581 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
###xml 475 480 <span type="species:ncbi:10090">mouse</span>
Pioglitazone treatment attenuates fibrosis and pro-inflammatory gene expression in AngII-infused mPPARgamma+/+, but not mPPARgamma-/-, mice. A: Cardiac fibrosis quantified by midventricular collagen area (n = 7-12/treatment group). B: Representative images of cardiac collagen expression (blue area). Ventricular OPN (C) and CD68 (D) mRNA expression were measured by real-time quantitative RT-PCR (n = 3-12/treatment group). Black and gray bars indicate WT and mPPARgamma-/- mouse data, respectively. *P < 0.05 vs. WT by Student's t test; daggerP < 0.05 vs. PBS; and double daggerP < 0.05 vs. AngII by one-way ANOVA. Pio, pioglitazone. (Please see  for a high-quality digital representation of this figure.)
###end p 57
###begin p 58
###xml 34 38 <span type="species:ncbi:10090">mice</span>
Cardiac hypertrophy in cPPARgamma mice
###end p 58
###begin p 59
###xml 23 24 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 139 140 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 262 263 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
Data are means +/- SD (n). Because one-way ANOVAs revealed significant differences between PBS- and AngII-infused mice for all phenotypes (P < 0.05), these two groups were analyzed using separate two-way ANOVAs to identify statistically significant differences (P < 0.05) in factor level means due to genotype (gene), treatment (drug), or the interaction between genotype and treatment (interaction) for each parameter. Significant differences due to genotype
###end p 59
###begin p 60
or treatment effects between specific groups were determined by Bonferroni post hoc analyses. Cardiomyocyte diameter, ANP/glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and BNP/GAPDH data were transformed prior to analysis to account for differences in normality or SDs within these groups (see research design and methods).
###end p 60
###begin p 61
SBP data were analyzed by both one- and two-way ANOVA. No significant differences were detected by either method.
###end p 61
###begin p 62
###xml 34 38 <span type="species:ncbi:10090">mice</span>
Cardiac hypertrophy in mPPARgamma mice
###end p 62
###begin p 63
###xml 23 24 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 210 211 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 307 308 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 421 422 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 641 642 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
Data are means +/- SD (n). PBS- and AngII-infused groups were analyzed separately because comparision between AngII- and PBS-infused groups revealed significant increases in all phenotypes upon AngII infusion (P < 0.05; one-way ANOVA). Differences in PBS+chow diet-treated mice were analyzed with Student's t test. AngII-infused groups were analyzed with two-way ANOVAs to identify statistically significant differences (P < 0.05) in factor level means due to genotype (gene), treatment (drug), or the interaction between genotype and treatment (interaction), and Bonferroni post-test analyses were used to identify significant differences (P < 0.05) in parameter means due to genotype or treatment effects between specific groups. SBP and heart-to-body weight data from AngII-infused mice were transformed prior to analysis to account for differences in normality or SDs within these groups (see research design and methods). Both heart-to-body weight ratio and cardiomyocyte diameter values demonstrated significant differences due to treatment by two-way ANOVA, but no significant differences were detected between group means in the post hoc analyses.
###end p 63
###begin p 64
SBP data were analyzed by both one- and two-way ANOVA. No significant differences were detected by either method.
###end p 64
###begin p 65
Two-way ANOVA comparing AngII+chow diet and AngII+Pio data.
###end p 65

